Summary Clinical anti-tumour efficacy of anti-cancer drugs is a function of dose intensity, i.e. the concentration -time profile in tumour tissue. Hence, information on drug concentration profiles in tumours is of critical importance but appropriate methods for measurement are lacking. The aim of the present study was to obtain, by microdialysis sampling, concentration -time profiles in a solid tumour (melanoma) of a model anti-cancer drug, carboplatin, and thereby to assess the scope of microdialysis for tumour pharmacokinetic studies in man. Six patients with cutaneous melanoma metastases at the extremities or body trunk, scheduled to receive carboplatin (400 mg m 2 i.v.) were studied. Carboplatin concentrations were monitored in serum, intratumoral and subcutaneous tissue. Calibration of the microdialysis probes was carried out in vitro and in vivo with use of the retrodialysis method. Complete carboplatin concentration vs time profiles in tumour and subcutaneous tissue were obtained. Major pharmacokinetic parameters (maximum concentration, time to maximum concentration, area under the curve, elimination half-life) were calculated for tissues and tumour/ serum concentration ratios for carboplatin were derived. Mean free concentrations of carboplatin in cutaneous melanoma metastases reached only about 50-60% of total serum levels; maximal intratumoral concentrations were 7.6 (±2.0; s.e.m.) Mg ml-', mean concentrations in subcutaneous tissue were similar to those in tumour.
It is generally agreed that clinical anti-tumour efficacy of anticancer drugs is a function of dose intensity, which is defined as the product of concentration (c) of a cytotoxic drug at the effect site and the time of cell exposure (t). Under in vitro conditions dose intensity is easily controlled; however, this is not the case in a clinical setting, when solid tumours are treated: the dose rate, i.e. total dose administered per time period is not necessarily correlated with the dose intensity in tumour cells (Jain, 1994; Eskey et al., 1992) . This lack of correlation is partly due to interindividual variability of pharmacokinetics of cytotoxic drugs, in that a given drug dose may yield highly variable plasma concentrations in individual patients (De Conti et al., 1973) . Nevertheless, even the plasma concentration-time profile is not necessarily a measure of the concentration-time profile at the target site, i.e. in the vicinity of tumour cells: local drug concentrations within the tumour are not only determined by plasma concentrations but also by the distribution from the central compartment (plasma) into the intracellular compartment within the tumour. It may be speculated that dose intensity may even be different for different tumour lesions in the same patient; this could be due to local differences in perfusion (Coughlin et al., 1994) or tissue permeability and may lead to the formation of 'tumour cell sanctuaries'. Lack of accessibility of cytotoxic drugs may play a role in clinical resistance of tumours to these agents (Skipper, 1965) .
Data on intratumoral concentrations of anti-cancer drugs are rare and are only available from biopsy studies (Hecquet et al., 1986; Los et al., 1993; Fujiwara et al., 1988; Vaden et al., 1993) , which cannot yield sufficient data on the time profile of exposure. However, information on drug concentration profiles in tumour tissue is necessary to optimise dosing and administration schedules, to select novel cytotoxic compounds with favourable tumour penetration characteristics and may help explain drug resistance in some patients.
Recently, the microdialysis technique, based on diffusion of analytes from the interstitial compartment through a semipermeable membrane, has been described for in vivo measurement of drug concentrations in the extracellular fluid (ECF) space in human tissues (Lonnroth et al., 1991; Stahle et al., 1991; Scheyer et al., 1994; Muller et al., 1995a) . The aim of this study was to obtain concentration-time profiles in the ECF of solid tumours of a model anti-cancer drug, carboplatin, and thereby to assess the scope of microdialysis for tumour pharmacokinetic studies in man.
Patients and methods

Patients
Six platinum-naive patients (four female, two male, mean age 58 + 3.6 years, WHO performance status <2) with metastatic malignant melanoma were included. All patients had cutaneous malignant melanoma metastases at the extremities or body trunk accessible to the microdialysis probe and were already scheduled to receive carboplatin (400 mg m-2) intravenously as a single agent. Admission of patients to the study was limited to the first carboplatin cycle. Concomitant medication included hydration, antiemetic and diuretic medication; other concomitant medication was continued.
Study protocol
The study protocol was approved by the ethics committee of the Vienna University Hospital. Written informed consent was obtained from all patients before study entry. Patients remained in a supine position throughout the study period. Room temperature was kept at 25°C. A plastic cannula (Venflon) was inserted into an antecubital vein to monitor serum concentrations of platinum at frequent intervals. The skin at the site of probe insertion was cleaned and disinfected. One dialysis probe was inserted intratumorally into a suitable cutaneous melanoma metastasis and a second probe was inserted into healthy subcutaneous connective tissue within a 10-15 cm distance to the first microdialysis probe. After the insertion of both microdialysis probes there was a 30 min equilibration period (Muller et al., 1995a) ; subsequently one 15 min microdialysis sample was taken (baseline level). Thereafter, carboplatin (400 mg m-2) was infused intravenously through a second cannula over a time period of 20 min. Sampling of microdialysates and blood were performed in 15 min intervals for up to 4 h, blood samples were taken at mid-time points of each microdialysis collection period.
Microdialysis procedure
The principles of microdialysis have been described in detail previously (Ungerstedt, 1991; L6nnroth et al., 1987; Morrison et al., 1991) . Briefly, microdialysis is based on sampling of analytes from the extracellular space by diffusion through a semipermeable membrane. This process is accomplished in vivo by using a microdialysis probe, which is constantly perfused with a physiological solution at a low flow-rate (0.5-10 ,ul min-m). Once the probe is implanted into the tissue, substances are filtered by diffusion from the extracellular fluid into the perfusion medium. Samples are collected and analysed.
In our experimental procedures, a commercially available microdialysis probe (CMA 10, CMA, Stockholm, Sweden) with a molecular cut-off of 20 kDa, an outer diameter of 500 ,um and a membrane length of 16 mm was used. Dialysis probes were inserted into a cutaneous melanoma metastasis and into nearby subcutaneous tissue by the following procedure. The surface of the disinfected skin was punctured vertically by a 20 gauge i.v. plastic cannula. The steel mandrin was removed. After an aspiration check (to confirm that the tip of the probe was not positioned in a blood vessel) the microdialysis probe was inserted into the plastic cannula. The plastic cannula was removed, leaving the probe under the surface of the skin. The proper position of the probe in the tumour was confirmed by high frequency (7.5 MHz) ultrasound scanning ( Figure 1 ). No local anaesthesia was used. The second microdialysis probe was inserted horizontally into the subcutaneous connective tissue in an identical fashion. The microdialysis system was connected and the probes were perfused by means of a precision infusion pump (Precidor, Ilfors-AG, Basle, Switzerland) at a constant flow rate of 1.5 pi min-'). Ringer's solution was used as perfusion fluid. Perfusate samples for measurement of drug levels were collected by means of a microfraction collection (CMA 120, CMA, Stockholm, Sweden) and stored at -20°C before analysis.
Owing to diffusion and sampling of the dialysate there is a , Palmsmeier et al., 1994 . The principle of this method relies on the assumption that the diffusion process is quantitatively equal in both directions through the semipermeable membrane. Therefore, carboplatin was added to the perfusion medium ('perfusate') and the disappearance rate through the membrane was calculated and taken as a measure of in vivo recovery. Thus, the in vivo recovery value was calculated as: Recovery (%) = 100 -(100 x carboplatindialysate x carboplatinperffimte 1) where carboplatindialyate is the carboplatin concentration in the dialysate and carboplatin fmraute is the carboplatin concentration in the perfusate.
In vivo recovery was assessed on separate study days by dialysing the tumour tissue with a perfusion medium containing 8 Mug ml-1 carboplatin for 120 min.
Study drug Carboplatin (Paraplatin, Bristol-Myers Squibb, Mayaguez, Puerto Rico) was administered as a single intravenous dose of 400 mg m-2, infusion time was 20 min. Analysis Platinum concentrations in serum and in the perfusate were measured by atomic absorption spectroscopy as described previously (McGahan et al., 1987 presented in It is also useful to consider the degree of between-patient variability of our measurements. For a given dose, the extent to which a solid tumour or non-malignant tissue is exposed to the cytotoxic drug is a function of plasma levels and of the extent to which the drug equilibrates between the plasma and the ECF space of the tissue. Hence, between-patient variability in tissue exposure is determined by the combined variabilities in plasma levels and tissue distribution. Whereas intersubject variability in plasma levels is readily assessed from classic pharmacokinetic data, there is very little information on variation regarding the distribution process.
In our study the variability in serum concentrations is reflected by the coefficient of variation (CV) of cmax-serum values, which was 18% for carboplatin. On the other hand, variability associated with the distribution process into tumour and subcutaneous tissue can be quantified by the CV of the Cmaxtumour/cmax-rerum ratio and the Cmax-scdcmax-serum ratio, which was 49% and 70% respectively, in our patient group. This is also borne out by the lack of correlation between serum-and tumour-or subcutaneous-AUC and cm,,x levels in our patients, which indicates that serum pharmacokinetic parameters are poor predictors of carboplatin (Jain, 1988 (Jain, , 1994 (Dollery, 1991 The use of rigid steel probes limits the use of microdialysis to very superficial tumours, such as melanoma as in our experiments. However, the availability of soft, flexible and small-diameter probes, which are inserted under ultrasound guidance, allows for the study even of deep -seated, less accessible tumour nodules. The duration of a single microdialysis experiment is limited only by the inconvenience caused to the experimental subject, particularly the requirement of resting in a supine position. However, Bolinder et al. (1993) , reported the use of special microdialysis probes for long-term studies. Major limitations of the microdialysis technique are the low recovery for molecules with large molecular weights or a high lipophilicity Carneheim and Stahle, 1991; Pich et al., 1993; Muller et al., 1995b) and the requirement for sensitive analytical techniques because of the small sample volumes and low concentrations obtained by microdialysis.
Microdialysis may also lend itself to the study of local drug metabolism in tumour tissue, which is of paramount importance for drug classes such as bioreductive agents (Palsmeier et al., 1994) . In addition, the technique may be applied to the study of concentration-effect relationships of anti-cancer agents by measuring the intratumoral release of local mediators or markers of cell damage.
In conclusion we have demonstrated that microdialysis sampling is suitable for measuring drug concentrations in the ECF space of solid tumours in humans. This technique may become a valuable addition for pharmacokinetic/pharmacodynamic studies in oncology.
